Transforming the standard of care for bloodstream infection detection: Bio101 elevates client’s chances of success with advanced financial and governance solutions

The client faced challenges transitioning from a private to an unlisted public company.

The switch and scaling introduced more complex reporting and further governance requirements.

Their existing finance function required additional firepower and expertise owing to the increased technical demands imposed by the structural change.

With the added complexity, robust cash forecasting and precise capital management practices were increasingly paramount to support the commercialization efforts and continued development of its R&D pipeline.

Bio101 was referred to the client by a number of people in the client’s network at a critical time in the company’s journey. The client required an outfit to step in to provide comprehensive financial and governance support.

Initially tasked with addressing their reporting requirements and enhancing their finance function – Bio101 developed detailed cash forecasts and valuation models, enabling effective capital management whilst supporting investment negotiations.

Working with Bio101 was not just a people-based solution but a chance to industrialise processes and systems to support company growth – tools like Weel, ApprovalMax and Dext helped greatly with controlling and managing their growing cashflow requirements.

This professional approach assisted in ensuring the company’s financial stability, positioning them for market expansion and further product developments.